The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The FDA grants Venclexta® Breakthrough Therapy Designation for the treatment of AML
On 28th July 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to Venclexta® (venetoclax), a BCL-2 oral inhibitor, in combination with Low Dose cytarabine (LDAC) for the treatment of elderly patients with previously untreated Acute Myeloid Leukemia (AML) who are ineligible for intensive chemotherapy.1
The BTD granted by the FDA was based on data from an ongoing phase I/II study (NCT02287233), which aimed to evaluate the safety and preliminary efficacy of Venclexa® at the RPD2 (600mg) in combination with LDAC in previously untreated elderly patients ≥65 years with AML. Results from the study showed that Venclexa® in combination with LDAC was tolerable and exhibited durable efficacy in elderly untreated AML patients. More results from this study are reported here.
Furthermore, one of the investigators in this study, Assoc. Prof. Andrew Wei, Alfred Hospital, Monash University, Melbourne, Australia, spoke to the AGP about the design and findings of this study. Of which, he highlighted that Venclexa® plus LDAC combination was “extremely well tolerated” and “the treatment results were quite remarkable” in elderly AML patients. He added that the long term survival rate in patients were also “very promising”.
References